Press release
Uveitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight
Uveitis Clinical Trials
"Uveitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.
The Uveitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Uveitis Pipeline Report:
• Uveitis Companies across the globe are diligently working toward developing novel Uveitis treatment therapies with a considerable amount of success over the years.
• Uveitis companies working in the treatment market are Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others, are developing therapies for the Uveitis treatment
• Emerging Uveitis therapies in the different phases of clinical trials are- Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others are expected to have a significant impact on the Uveitis market in the coming years.
• In August 2023, Tarsier Pharma, an advanced clinical-stage biotechnology company focused on developing dazdotuftide (previously TRS), a groundbreaking New Chemical Entity for individuals with immune-mediated diseases, has disclosed findings from the TRS4VISION Trial, which investigated noninfectious anterior uveitis. Although the primary endpoint was not achieved, a subsequent analysis of the data reveals an eagerly awaited clinical profile, showcasing a combination of safety and effective resolution of inflammation. This outcome holds promise for the treatment of noninfectious uveitis, particularly in managing uveitic glaucoma.
• In April 2023, The World Health Organization (WHO) has placed Tarsier Pharma Ltd., a late-stage pharmaceutical business, on the INN Recommended List and awarded its first-in-class immunomodulator TRS an International Nonproprietary Name (INN) of "Dazdotuftide."
• In September 2021, A Phase III randomized, active-controlled, double-masked trial was started by Tarsier Pharma to assess the safety and effectiveness of TRS01 eye drops in treating patients with active non-infectious anterior uveitis, including those with uveitic glaucoma.
Uveitis Overview
The illness condition known as uveitis causes inflammation in the eyes. A wide range of disease types together known as uveitis have been estimated to cause 10% of blindness. Acute, intermediate, posterior, and panuveitis are the four main categories of uveitis according to the eye's anatomical involvement.
Get a Free Sample PDF Report to know more about Uveitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Uveitis Drugs Under Different Phases of Clinical Development Include:
• Laquinimod: Active Biotech AB
• EYS606: Eyevensys
• ESK-001: Alumis Inc
• Baricitinib: Eli Lilly and Company
• TRS01: Tarsier Pharma
Uveitis Route of Administration
Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Uveitis Molecule Type
Uveitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Uveitis Pipeline Therapeutics Assessment
• Uveitis Assessment by Product Type
• Uveitis By Stage and Product Type
• Uveitis Assessment by Route of Administration
• Uveitis By Stage and Route of Administration
• Uveitis Assessment by Molecule Type
• Uveitis by Stage and Molecule Type
DelveInsight's Uveitis Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Uveitis product details are provided in the report. Download the Uveitis pipeline report to learn more about the emerging Uveitis therapies at:
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Uveitis Therapeutics Market include:
Key companies developing therapies for Uveitis are - Novartis AG, Bausch Health Inc., AbbVie Inc., Eyegate Pharmaceuticals, Inc., Alimera Science Inc., EyePoint Pharmaceuticals, Santen Pharmaceuticals, Clearside Biomedical inc., and others.
Uveitis Pipeline Analysis:
The Uveitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Uveitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveitis Treatment.
• Uveitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Uveitis drugs and therapies-
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Uveitis Pipeline Market Drivers
• Increasing Prevalence of Uveitis, increase in Research and developmental Activities are some of the important factors that are fueling the Uveitis Market.
Uveitis Pipeline Market Barriers
• However, high Cost associated with the treatment, lack of skilled professionals and other factors are creating obstacles in the Uveitis Market growth.
Scope of Uveitis Pipeline Drug Insight
• Coverage: Global
• Key Uveitis Companies: Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others
• Key Uveitis Therapies: Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others
• Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
• Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers
Request for Sample PDF Report for Uveitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Uveitis Report Introduction
2. Uveitis Executive Summary
3. Uveitis Overview
4. Uveitis- Analytical Perspective In-depth Commercial Assessment
5. Uveitis Pipeline Therapeutics
6. Uveitis Late Stage Products (Phase II/III)
7. Uveitis Mid Stage Products (Phase II)
8. Uveitis Early Stage Products (Phase I)
9. Uveitis Preclinical Stage Products
10. Uveitis Therapeutics Assessment
11. Uveitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Uveitis Key Companies
14. Uveitis Key Products
15. Uveitis Unmet Needs
16 . Uveitis Market Drivers and Barriers
17. Uveitis Future Perspectives and Conclusion
18. Uveitis Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Healthcare Pipeline Analysis: https://www.delveinsight.com/consulting/pipeline-assessment-services
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Menorrhalgia Market Size: https://www.delveinsight.com/report-store/menorrhalgia-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-type-2-market-insight
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acanthamoeba Keratitis Market: https://www.delveinsight.com/report-store/acanthamoeba-keratitis-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/merger-and-acquisition
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight here
News-ID: 3850042 • Views: …
More Releases from DelveInsight Business Research
Sarcopenia Market Expected to Experience Major Growth by 2034, According to Delv …
DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Sarcopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sarcopenia Market Forecast
https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Sarcopenia…
Chronic Spontaneous Urticaria Market Set to Grow Substantially Through 2034, Del …
DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Spontaneous Urticaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Spontaneous Urticaria…
Chronic Kidney Disease Market to Show Remarkable Growth Trends from 2024 to 2034 …
The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.
DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney…
Beta Thalassemia Market Predicted to See Upsurge Through 2034, Highlights DelveI …
DelveInsight's "Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Beta Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Beta Thalassemia Market Forecast
https://www.delveinsight.com/sample-request/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts…
More Releases for Uveitis
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
Uveitis Treatment Market: Global Market Of Uveitis Disease Is Estimated To Reach …
Uveitis Treatment Market
Precision Business Insights (PBI) in its report titled “Global Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
Uveitis is swelling of the middle layer of the eye,…
Uveitis Therapeutic and Disease Pipeline Review H1
Summary
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or…
Anterior Uveitis Market: An Industry Case Study
Uveitis is the inflammation of the uveal region of the eye, most commonly by an infection. Uvea is a group of pigmented and non pigmented tissues lying in the middle among the three layers that make the eye. Uvea again consists of three layers: iris, cilliary body and the choroid. The uvea is also known as the uveal tract in some medical circles, this tract is necessary for the nutrition…
Uveitis Treatment Market By Indication (Anterior uveitis, Intermediate uveitis, …
Uveitis is a combined condition of inflammation and swelling of the eyes. Uvea comprises of three parts Iris, ciliary body (small ring shape muscles behind iris and choroid), and choroid (it is the layer of tissue between retina and sclera), which decides eye color and helps eye in focusing and absorbing light. Uveitis can be caused by eye problems, autoimmune disease, HIV, multiple sclerosis, reactive arthritis, Kawasaki disease tuberculosis, and…
